学术周报 · IF≥10 或专科旗舰刊

胃肠外科领域文献阅读汇编

2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
收录论文
33
临床研究
23
基础研究
10
IF≥20
1
IF 10-20
19
子领域
7
期刊种类
16
数据日期
2026-11-06

★本周 Top 10 高影响力文献

#论文期刊IF
1Helicobacter pylori Infection Remodels Neutrophil-Derived Extracellular Vesicles, Promoting Stress a...Journal of extracellular vesiclesIF 21.7
2Cancer-associated fibroblast-derived POSTN as a metabolic "switch" shapes lipid-stressed macrophage ...Redox biologyIF 16.2
3Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chem...Science translational medicineIF 15.6
4psiTPTE22-HERV functions as a tumor suppressor by inhibiting PI3K/AKT/mTOR/EIF4E signaling.Genes & diseasesIF 14.6
5SERHL regulates invasion and metastasis through KLF16-PLCB1/PRKCA signaling in gastric cancer cells.Genes & diseasesIF 14.6
6Therapeutic resistance in cancer: lncRNAs as modulators and targets for cancer therapy.Genes & diseasesIF 14.6
7Development and Validation of an Interpretable Machine-Learning Model for Predicting Suboptimal Clin...MedCommIF 14.1
8Efficacy and Safety of ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Conversion T...MedCommIF 14.1
9Gastric Cancer: Epidemiology, Risk Factors, Pathogenesis, Clinical Features, Diagnosis, and Manageme...MedCommIF 14.1
10Short- and Long-Term Control of Hypertension After Bariatric Surgery: A 10-Year Prospective Study.MedCommIF 14.1

Ŧ期刊分布统计

期刊篇数IF
Annals of surgery7IF 7.4
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association6IF 0.0
MedComm4IF 14.1
Genes & diseases3IF 14.6
Cancer letters2IF 11.8
Endoscopy1IF 11.8
Science translational medicine1IF 15.6
ESMO open1IF 10.6
Journal of extracellular vesicles1IF 21.7
Pharmacological research1IF 12.2

1胃癌/胃切除 (14篇)

临床研究 (9篇)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2026-11-05 PMID: 42986509
Postoperative recurrence remains a major cause of mortality in gastric cancer. Although systemic immune dysregulation and peritoneal immune responses are implicated in disease progression, their interrelationship and prognostic significance remain incompletely understood. Patients with gastric adenocarcinoma undergoing curative gastrectomy were prospectively enrolled. Multiparameter flow cytometry profiled immune-cell subsets in peripheral blood (n = 77) and omental tissue (n = 53). Associations with recurrence-free survival (RFS) were evaluated using Cox proportional hazards models, including analyses adjusted for pathological stage (pStage) and other clinicopathological factors. Spearman's rank correlation analyses evaluated relationships within and between systemic and omental immune compartments. Exploratory integrated Cox models combining systemic and omental immune-cell variables were also examined. In peripheral blood, higher proportions of several activated or differentiated T-cell subsets, including CD8⁺ICOS⁺, effector-memory, and PD1-expressing populations, together with suppressive myeloid-cell populations, were associated with shorter RFS, whereas CD19⁺ B cells were associated with favorable outcomes. In the omentum, higher proportions of CD4⁺PD1+ T cells, CD56⁺CD16⁺ cells, and suppressive myeloid-cell populations were associated with shorter RFS, whereas CD19⁺CD21⁺ B cells were associated with prolonged RFS. Significant cross-compartment correlations were observed. A model combining systemic and omental immune-cell variables with pStage showed an optimism-corrected C-index of 0.828, compared with 0.642 for pStage alone. Systemic and omental immune profiles are associated with postoperative recurrence in gastric cancer and show cross-compartment concordance. Exploratory integrated analyses suggest complementary prognostic information beyond pStage, supporting validation in larger independent cohorts.
中文摘要:胃癌术后复发仍是主要死亡原因。全身免疫失调与腹膜免疫反应均与疾病进展有关,但二者之间的关系及预后意义尚未完全明确。前瞻性纳入接受根治性胃切除术的胃腺癌患者,用多参数流式细胞术分析外周血(n=77)和大网膜组织(n=53)中的免疫细胞亚群。采用Cox比例风险模型评估其与无复发生存期(RFS)的关联,并纳入按病理分期(pStage)及其他临床病理因素校正的分析。用Spearman秩相关分析评估全身与大网膜免疫区室内部及彼此之间的关系,并探索性构建联合全身和大网膜免疫细胞变量的整合Cox模型。外周血中,CD8⁺ICOS⁺、效应记忆及表达PD1的T细胞亚群等活化或分化T细胞比例较高,连同抑制性髓系细胞群体,与较短RFS相关;CD19⁺ B细胞与较好结局相关。大网膜中,CD4⁺PD1+ T细胞、CD56⁺CD16⁺细胞及抑制性髓系细胞比例较高与较短RFS相关;CD19⁺CD21⁺ B细胞与较长RFS相关。观察到显著的跨区室相关性。将全身和大网膜免疫细胞变量与pStage联合的模型,其乐观校正C指数为0.828,而仅用pStage为0.642。胃癌的全身与大网膜免疫谱与术后复发相关,并显示跨区室一致性。探索性整合分析提示其可提供超出pStage的补充预后信息,支持在更大独立队列中验证。
Endoscopy IF 11.8 2026-11-04 PMID: 42982055
The cost-utility of a mature cancer screening programme can shift as disease incidence, costs, and population risk change. We examined how these changes affected Korea's National Cancer Screening Program (NCSP) for gastric cancer by comparing two hypothetical cohorts parameterized with 2012 and 2022 conditions. Two structurally identical state-transition models simulated biennial endoscopic screening versus no organised screening in adults aged 40-79 years over a lifetime horizon, incorporating period-specific screen-detected health-state distributions, effective screening sensitivity, NCSP participation, and treatment costs. Incremental cost-utility ratios (ICURs) per quality-adjusted life-years (QALYs) were calculated in period-specific prices. For cross-period comparison, incremental costs were converted to 2025 KRW, and net monetary benefit (NMB) was calculated at a willingness-to-pay threshold of KRW 50 million/QALY(USD 40,000). The ICUR increased from KRW 9.62 million/QALY(USD 7,694) in the 2012 model to KRW 48.62 million/QALY(USD 38,895) in the 2022 model, and NMB in 2025 KRW decreased from KRW 1.73 million to KRW -0.05 million per person. In 2022, the ICUR was KRW 28.20 million/QALY(USD 22,558) for men and KRW 84.37 million/QALY(USD 67,497) for women. The increase was driven mainly by a shift in the screen-detected histologic composition of neoplasia toward lower-risk non-adenomatous findings and by higher costs. The cost-effectiveness of uniform biennial endoscopic screening in Korea declined substantially between 2012 and 2022 and the 2022 results were markedly less favourable for women than for men. These findings support periodic reassessment of mature screening programmes and further evaluation of differentiated screening approaches.
中文摘要:成熟的癌症筛查项目的成本效用会随疾病发病率、成本和人群风险变化而改变。我们比较两个以2012年和2022年条件参数化的假设队列,考察这些变化如何影响韩国国家癌症筛查项目(NCSP)的胃癌筛查。两个结构相同的状态转移模型模拟40-79岁成人终生接受每两年一次内镜筛查与不接受有组织筛查的情况,纳入各时期的筛查检出健康状态分布、有效筛查灵敏度、NCSP参与率和治疗成本。按各时期价格计算每质量调整生命年(QALY)的增量成本效用比(ICUR)。为进行跨期比较,增量成本换算为2025年韩元,并按每QALY 5000万韩元(4万美元)的支付意愿阈值计算净货币收益(NMB)。ICUR从2012年模型的962万韩元/QALY(7694美元)升至2022年模型的4862万韩元/QALY(38895美元),2025年韩元计的NMB从每人173万韩元降至-5万韩元。2022年男性ICUR为2820万韩元/QALY(22558美元),女性为8437万韩元/QALY(67497美元)。上升主要由筛查检出肿瘤的组织学构成转向低风险非腺瘤性发现以及成本升高驱动。韩国统一每两年一次内镜筛查的成本效果在2012年至2022年间明显下降,2022年结果对女性明显不如男性有利。这些发现支持对成熟筛查项目进行定期重新评估,并进一步评价差异化筛查策略。
Science translational medicine IF 15.6 2026-11-04 PMID: 42981428
Previous studies combining the multikinase inhibitor regorafenib with a PD-1 inhibitor showed promising activity in gastric cancer. We conducted a phase 1b/2 trial (NCT05394740) of first-line regorafenib, nivolumab, and chemotherapy in 30 patients with mismatch repair-proficient gastric cancer and investigated its impact on the tumor microenvironment. The primary end point was met; 22 of 30 patients showed objective tumor response (73%; 80% confidence interval, 60.3 to 83.8). Single-cell RNA and T cell receptor sequencing were performed on biopsy samples at baseline, during treatment, and at disease progression. The combination treatment increased tumor antigen-reactive CD8+ T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8+ regulatory T cells, LRRC15+ cancer-associated fibroblasts (CAFs), RGS5+ pericytes, and APLN+ tip cells. At progression, LRRC15+ CAFs and APLN+ tip cells remained reduced, activated CCR8+ regulatory T cells reexpanded, and additional treatment-resistant subsets emerged, including APOC1+ lipid-associated macrophages. In murine models of acquired resistance, therapeutic targeting of these suppressive immune cell populations with antibodies against CCR8 or TREM2 in combination with PD-1 blockade restored antitumor immunity. These findings demonstrate dynamic remodeling of the tumor microenvironment and suggest potential therapeutic targets.
中文摘要:既往研究显示,多激酶抑制剂瑞戈非尼联合PD-1抑制剂在胃癌中具有较好活性。我们在30例错配修复功能完整的胃癌患者中开展了一线瑞戈非尼、纳武利尤单抗和化疗的1b/2期试验(NCT05394740),并考察该方案对肿瘤微环境的影响。主要终点已达到,30例中22例出现客观肿瘤缓解(73%;80%置信区间为60.3至83.8)。对基线、治疗期间和疾病进展时的活检样本进行了单细胞RNA测序和T细胞受体测序。联合治疗增加了肿瘤抗原反应性CD8+ T细胞和M1样促炎巨噬细胞,减少了免疫抑制和促肿瘤细胞群,包括活化的CCR8+调节性T细胞、LRRC15+癌相关成纤维细胞、RGS5+周细胞和APLN+尖端细胞。疾病进展时,LRRC15+癌相关成纤维细胞和APLN+尖端细胞仍减少,活化的CCR8+调节性T细胞再次扩增,并出现其他治疗耐药亚群,包括APOC1+脂质相关巨噬细胞。在获得性耐药小鼠模型中,用抗CCR8或抗TREM2抗体联合PD-1阻断靶向这些抑制性免疫细胞群,恢复了抗肿瘤免疫。这些结果显示了肿瘤微环境的动态重塑,并提示潜在的治疗靶点。
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2026-11-04 PMID: 42980995
Despite increasing global adoption of robotic approaches, the comparative effectiveness of robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer is uncertain, particularly regarding long-term oncologic outcomes. This phase III randomized controlled trial (RCT) enrolled 241 patients with resectable gastric cancer (clinical stages I-III) between April 1, 2018, and October 31, 2020. Patients were randomly assigned to undergo either robotic gastrectomy or laparoscopic gastrectomy. The primary endpoint was postoperative intra-abdominal infectious complications (previously reported). Secondary endpoints included long-term oncologic outcomes, specifically relapse-free survival, overall survival and patterns of recurrence. This study enrolled 241 patients, with 236 patients in the modified intention-to-treat population. The 5-year relapse-free survival in the modified intention-to-treat population did not significantly differ between the laparoscopic gastrectomy and robotic gastrectomy groups (69% vs. 75%). Similarly, overall survival was not significantly different between the groups (71% vs. 79%). The 5-year cumulative incidence of primary disease-specific death was comparable between the groups (16.1% vs. 11.6%). Patterns of recurrence did not differ between them. In subgroup analyses, the robotic gastrectomy group demonstrated significantly better overall survival than the laparoscopic gastrectomy group among male patients (HR, 0.48; 95% CI, 0.25-0.95). Among patients that underwent distal gastrectomy, the robotic gastrectomy group showed a significantly lower cumulative incidence of primary disease-specific death than the laparoscopic gastrectomy group (HR, 0.24; 95% CI, 0.07-0.81). In this RCT, secondary endpoint analyses showed no statistically significant differences in 5-year relapse-free survival or overall survival between laparoscopic gastrectomy and robotic gastrectomy. umin.ac.jp/ctr Identifier UMIN000031536.
中文摘要:尽管机器人手术方式在全球的应用不断增加,机器人胃切除术与腹腔镜胃切除术治疗胃癌的比较效果仍不确定,长期肿瘤学结局尤其如此。这项III期随机对照试验于2018年4月1日至2020年10月31日纳入241例可切除胃癌患者(临床分期I-III期),随机分配接受机器人胃切除术或腹腔镜胃切除术。主要终点为术后腹腔内感染性并发症,此前已报告。次要终点包括长期肿瘤学结局,具体为无复发生存、总生存和复发模式。研究纳入241例患者,改良意向治疗人群为236例。改良意向治疗人群中,腹腔镜胃切除组与机器人胃切除组的5年无复发生存率无显著差异(69%对75%)。两组总生存率同样无显著差异(71%对79%)。两组原发病特异性死亡的5年累积发生率相近(16.1%对11.6%)。复发模式两组无差异。亚组分析中,男性患者接受机器人胃切除的总生存优于腹腔镜胃切除(HR 0.48,95%CI 0.25-0.95)。接受远端胃切除的患者中,机器人胃切除组的原发病特异性死亡累积发生率显著低于腹腔镜胃切除组(HR 0.24,95%CI 0.07-0.81)。该随机对照试验的次要终点分析显示,腹腔镜胃切除与机器人胃切除的5年无复发生存或总生存均无统计学显著差异。umin.ac.jp/ctr Identifier UMIN000031536。
MedComm IF 14.1 2026-11 PMID: 42984816
This single-center randomized controlled trial assessed the efficacy and safety of the ramucirumab plus nab-paclitaxel, lobaplatin, and S-1(RNPLS) regimen for conversion therapy in unresectable advanced gastric cancer. Seventy patients were equally assigned to receive either ramucirumab, nab-paclitaxel, lobaplatin, and S-1(RNPLS) therapy or nab-paclitaxel, lobaplatin, and S-1(NPLS) chemotherapy alone. Primary endpoints included pathological complete response (pCR) and secondary endpoints encompassed R0 resection rate, objective response rate (ORR), the disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and adverse events (AE). Although the difference in pCR rate was statistically insignificant between the two groups, the RNPLS group achieved significantly higher ORR, DCR, and R0 resection rate. Moreover, the RNPLS regimen yielded prolonged PFS, longer duration of response, and promising preliminary OS. While hypertension occurred more frequently in the RNPLS group, the incidence of grade ≥3 AEs was low and comparable in both cohorts. This exploratory single-center randomized trial showed preliminary favorable efficacy of RNPLS regimen for conversion therapy in unresectable advanced gastric cancer with manageable toxicity. ClinicalTrials.gov: NCT06169410.
中文摘要:这项单中心随机对照试验评估雷莫西尤单抗联合白蛋白结合型紫杉醇、洛铂和替吉奥(RNPLS)方案用于不可切除晚期胃癌转化治疗的有效性与安全性。70例患者被平均分配接受雷莫西尤单抗、白蛋白结合型紫杉醇、洛铂和替吉奥(RNPLS)治疗,或仅接受白蛋白结合型紫杉醇、洛铂和替吉奥(NPLS)化疗。主要终点为病理完全缓解(pCR),次要终点包括R0切除率、客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)、缓解持续时间(DOR)及不良事件(AE)。两组pCR率差异无统计学意义,RNPLS组ORR、DCR和R0切除率显著更高。RNPLS方案还带来PFS延长、缓解持续时间延长以及初步OS获益。RNPLS组高血压发生更频繁,但两组≥3级AE发生率均较低且相近。这项探索性单中心随机试验显示,RNPLS方案用于不可切除晚期胃癌转化治疗具有初步良好疗效,毒性可管理。ClinicalTrials.gov:NCT06169410。
ESMO open IF 10.6 2026-11-03 PMID: 42976418
Results from the third interim analysis of the phase 3 KEYNOTE-585 study (NCT03221426) showed superior pathological complete response (pCR) with perioperative pembrolizumab and chemotherapy followed by adjuvant pembrolizumab versus placebo plus chemotherapy, then adjuvant placebo in locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma; differences in event-free survival (EFS) were not statistically significant. We present results from a complementary cohort that evaluated pembrolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) versus placebo plus FLOT. KEYNOTE-585 is a randomized, phase 3 study conducted at 143 medical centers. Participants were randomly assigned 1 : 1 to pembrolizumab plus FLOT or placebo plus FLOT. In this exploratory cohort, the primary endpoint was safety. Post hoc exploratory endpoints included pCR rate per the Mandard scale by blinded independent central review, EFS per RECIST v1.1 by investigator, and overall survival (OS). Overall, 203 participants were randomly assigned (pembrolizumab group, n = 100; placebo group, n = 103). Median time from randomization to data cut-off (16 February 2024) was 43.8 months (range, 36.5-69.8). Grade 3 or 4 treatment-related adverse event rates were 72.7% and 62.1%, respectively. Treatment-related deaths occurred in three participants (3.0%) in the pembrolizumab group and one participant (1.0%) in the placebo group. The pCR rate was 17.0% [95% confidence interval (CI), 10.2-25.8] in the pembrolizumab group and 6.8% (95% CI, 2.8-13.5) in the placebo group. Median EFS was not reached (NR; 95% CI, 28.2-NR) versus 31.6 months (95% CI, 22.8-NR), respectively [hazard ratio (HR) 0.75, 95% CI 0.50-1.13]. Median OS was NR in either group (HR 0.81, 95% CI 0.53-1.25); 36-month OS rates were 66.0% and 59.2%. Neoadjuvant/adjuvant pembrolizumab plus FLOT was feasible and showed an acceptable safety profile. Exploratory efficacy endpoints showed numerical trends consistent with those of the main cohort in locally advanced resectable gastric or gastroesophageal junction adenocarcinoma.
中文摘要:KEYNOTE-585研究(NCT03221426)第三次期中分析显示,在局部晚期可切除胃或胃食管结合部腺癌中,围手术期帕博利珠单抗联合化疗、随后辅助帕博利珠单抗,相比安慰剂联合化疗、随后辅助安慰剂,病理完全缓解(pCR)更优;无事件生存(EFS)差异无统计学意义。一个补充队列评估帕博利珠单抗联合氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛(FLOT)对比安慰剂联合FLOT。KEYNOTE-585是在143个医疗中心开展的随机3期研究。参与者按1:1随机分配至帕博利珠单抗联合FLOT或安慰剂联合FLOT。该探索性队列的主要终点为安全性。事后探索性终点包括盲态独立中心评审按Mandard分级评估的pCR率、研究者按RECIST v1.1评估的EFS和总生存(OS)。共203名参与者随机分配(帕博利珠单抗组n=100;安慰剂组n=103)。从随机化至数据截止(2024年2月16日)的中位时间为43.8个月(范围36.5-69.8)。3级或4级治疗相关不良事件发生率分别为72.7%和62.1%。治疗相关死亡在帕博利珠单抗组有3名参与者(3.0%),安慰剂组有1名(1.0%)。pCR率在帕博利珠单抗组为17.0%[95%置信区间(CI)10.2-25.8],安慰剂组为6.8%(95%CI 2.8-13.5)。中位EFS分别为未达到(NR;95%CI 28.2-NR)和31.6个月(95%CI 22.8-NR)[风险比(HR)0.75,95%CI 0.50-1.13]。两组中位OS均未达到(HR 0.81,95%CI 0.53-1.25);36个月OS率分别为66.0%和59.2%。新辅助/辅助帕博利珠单抗联合FLOT可行,安全性可接受。探索性疗效终点显示数值趋势与主队列在局部晚期可切除胃或胃食管结合部腺癌中一致。
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2026-11-03 PMID: 42975840
Evidence of income-based disparities in gastric cancer outcomes exist; however, little research has explored income and gastric cancer outcomes within North America. We investigated the association between individual income and diagnosis with stage IV gastric cancer and death from any cause in the five years following diagnosis. Canadians diagnosed with gastric cancer between 2010 and 2019 were included using Canadian Census Health and Environmental Cohorts (CanCHEC) linked to the Canadian Cancer Registry, and national hospitalization and vital statistics databases. Individual income was determined prior to the cancer diagnosis and categorized into quintiles (lowest to highest) nationally for each census year. Multivariable logistic regression estimated the association between income and stage IV gastric cancer. Multivariable Cox proportional-hazards regression estimated the association with death from any cause. 8,545 Canadians with gastric cancer were included. We did not observe an association between individual income and presentation with stage IV diagnosis (p = 0.26). We observed a significant association between individual income quintile and death from any cause in the five years following diagnosis (p = 0.003), with patients within the lowest income quintile having 1.18 times the risk of death when compared to patients within the highest income quintile (HR = 1.18; 95% CI: 1.08-1.29). These findings suggest that income-related barriers may influence outcomes after diagnosis rather than stage at presentation. Future research understanding pathways to worse gastric cancer outcomes for individuals with low income in low incidence countries with universal health care systems that prioritize patient, survivor and caregiver perspectives is needed.
中文摘要:已有证据显示胃癌结局存在收入差异,但北美地区关于收入与胃癌结局的研究较少。分析个体收入与IV期胃癌诊断以及诊断后五年内全因死亡之间的关联。纳入2010年至2019年确诊胃癌的加拿大人,数据来自与加拿大癌症登记、全国住院和生命统计数据库链接的加拿大人口普查健康与环境队列(CanCHEC)。个体收入在癌症诊断前确定,并按每个普查年份在全国范围内分为五分位(最低至最高)。多变量logistic回归估计收入与IV期胃癌的关联,多变量Cox比例风险回归估计收入与全因死亡的关联。共纳入8545名胃癌患者。未观察到个体收入与IV期诊断存在关联(p=0.26)。观察到个体收入五分位与诊断后五年内全因死亡存在显著关联(p=0.003),最低收入五分位患者死亡风险为最高收入五分位患者的1.18倍(HR=1.18;95%CI:1.08-1.29)。这些结果提示,收入相关障碍可能影响诊断后的结局,而非诊断时的分期。未来需要在胃癌低发病率、实行全民医疗体系的国家开展研究,理解低收入个体胃癌结局更差的路径,并重视患者、生存者和照护者的视角。
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2026-11-02 PMID: 42970231
Testing for HER2, PD-L1, MSI/MMR, and CLDN18 guides first-line treatment selection for unresectable advanced or recurrent gastric cancer. Our first nationwide survey revealed substantial interinstitutional variation in HER2 and PD-L1 results and identified fixation time as one contributing factor. The present survey assessed testing timing and location and expanded the analysis to CLDN18 and MSI/MMR. A questionnaire survey was conducted among 447 institutions certified by the Japanese Gastric Cancer Association. Testing volumes, timing, and location for the four biomarkers were analyzed together with results from the previous survey. Responses were obtained from 155 institutions (34.7%). Nearly all institutions performed all four biomarker tests, and 81.9% conducted simultaneous testing before first-line therapy. In-house testing rates were 80.1% for HER2-IHC, 34.6% for CLDN18, 26.3% for MMR, 25.6% for HER2-ISH, 16.7% for PD-L1, and 9.6% for MSI. After adjustment for annual testing volume, institutions performing ISH in-house had higher odds of HER2 IHC 2 + results in surgical specimens, whereas the association did not reach statistical significance in biopsy specimens. Overall CLDN18 positivity was 38.6% and was significantly higher in institutions performing in-house testing after adjustment for testing volume. HER2 negativity correlated positively with CLDN18 positivity among institutions performing both tests in-house. Although simultaneous four-biomarker testing is widely adopted in Japan, the use of in-house versus outsourced testing varies by biomarker and institution and is associated with differences in reported positivity rates. Our findings underscore the need for continued quality assurance and standardization to ensure reliable biomarker assessment and appropriate treatment selection.
中文摘要:HER2、PD-L1、MSI/MMR和CLDN18检测可指导不可切除晚期或复发性胃癌一线治疗选择。首次全国调查显示HER2和PD-L1结果在机构间差异明显,并发现固定时间是一个相关因素。本次调查评估检测时机和地点,并将分析扩展至CLDN18和MSI/MMR。向日本胃癌学会认证的447家机构发放问卷,分析四种标志物的检测量、时机和地点,并结合前次调查结果。共155家机构回复(34.7%)。几乎所有机构均开展四种标志物检测,81.9%在一线治疗前同时检测。院内检测率分别为HER2-IHC 80.1%、CLDN18 34.6%、MMR 26.3%、HER2-ISH 25.6%、PD-L1 16.7%、MSI 9.6%。按年检测量校正后,开展院内ISH检测的机构手术标本中HER2 IHC 2+结果的比值更高,但活检标本中该关联未达统计学显著。CLDN18总阳性率为38.6%,按检测量校正后,开展院内检测的机构显著更高。在同时开展两种院内检测的机构中,HER2阴性性与CLDN18阳性性呈正相关。日本广泛采用四种标志物同时检测,但院内检测与外包检测的使用因标志物和机构而异,并与报告阳性率差异相关。结果强调需持续开展质量保证和标准化,以确保可靠的标志物评估和恰当的治疗选择。
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2026-10-31 PMID: 42965650
This study aimed to evaluate the association of proximal margin (PM) status and length with oncologic outcomes following curative gastrectomy for gastric and gastroesophageal junction adenocarcinomas (GA and GEJA) using a contemporary Western multi-institutional cohort. Patients who underwent curative-intent resection for GA and Siewert III GEJA from 2016 to 2020 at two U.S. institutions were included. Outcomes were compared between patients with positive and negative PMs. Margin length was analyzed continuously in millimeters using multivariable Cox proportional hazards models among all patients with negative PMs and separately among those with p/ypN0-N1 disease. The primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Among 412 patients, 54.9% received neoadjuvant chemotherapy, and 80.1% underwent minimally invasive surgery. Overall, 399 patients (96.8%) had negative PMs and 13 (3.2%) had positive PMs. Positive PMs were associated with larger tumors, advanced p/ypT and p/ypN stage, and perineural invasion. Among 343 patients with negative PMs and available margin measurements, PM length was not associated with RFS or OS in either the entire cohort or the p/ypN0-N1 subgroup (n=232). Pathologic TNM stage and age were independently associated with both RFS and OS in multivariable analyses. In this contemporary Western multi-institutional cohort, increasing negative PM length was not associated with improved oncologic outcomes, including among patients with p/ypN0-N1 disease. Positive PMs were uncommon and occurred predominantly in patients with advanced disease.
中文摘要:本研究利用当代西方多中心队列,评估胃及胃食管结合部腺癌(GA与GEJA)根治性胃切除术后近端切缘(PM)状态与长度同肿瘤学结局的关联。纳入2016至2020年间在美国两家机构因GA及Siewert III型GEJA接受根治性切除的患者,比较PM阳性与阴性者的结局。在全部PM阴性患者中按毫米连续分析切缘长度,并在p/ypN0-N1期患者中另行分析,采用多变量Cox比例风险模型。主要结局为无复发生存(RFS)与总生存(OS)。412例患者中54.9%接受新辅助化疗,80.1%接受微创手术。399例(96.8%)PM阴性,13例(3.2%)PM阳性。PM阳性与肿瘤较大、p/ypT与p/ypN分期较晚及神经侵犯相关。在343例PM阴性且切缘长度可测量的患者中,无论整个队列还是p/ypN0-N1亚组(n=232),PM长度均与RFS或OS无关。多变量分析中,病理TNM分期与年龄独立关联RFS和OS。在这一当代西方多中心队列中,增加阴性PM长度并未改善肿瘤学结局,p/ypN0-N1期患者亦如此。PM阳性并不常见,主要见于进展期患者。

基础研究 (5篇)

Journal of extracellular vesicles IF 21.7 2026-11 PMID: 42976050
Helicobacter pylori is a Gram-negative bacterium that establishes colonization in the human stomach and is estimated to infect over half of the global population. It is recognized as a significant causative agent of chronic gastritis, peptic ulcers, and gastric cancer. Neutrophils play a central role in innate defence against H. pylori; however, dysregulated neutrophil activation contributes to epithelial injury and persistent inflammation. Here, we show that H. pylori enhance neutrophil exocytosis and stimulates the release of extracellular vehicles (EVs) with distinct biophysical and molecular characteristics. Infected neutrophils released smaller and more abundant EVs than uninfected controls. These H. pylori-induced neutrophil EVs (HPN-EVs) suppressed PI3K/Akt signalling, increased reactive oxygen species, disrupted mitochondrial integrity, and induced cytochrome c release, caspase activation, and apoptosis in infected gastric epithelial cells. Proteomics profiling revealed enrichment of neutrophil granule proteins, particularly LL-3, and depletion of proteins associated with cellular homeostasis. EV-mediated LL-37 delivery reproduced key pro-apoptotic effects of HPN-EVs, supporting its functional role in epithelial injury. Consistent with these findings, circulating EVs from H. pylori-infected patients exhibited elevated LL-37 levels and induced similar pro-apoptotic responses. Together, these findings identify LL-37-enriched HPN-EVs as important mediators of neutrophil-epithelial crosstalk and investigating EV-associated cargo as a potential therapeutic target in H. pylori-associated disease.
中文摘要:幽门螺杆菌是一种革兰阴性细菌,可在人胃内定植,估计全球超过一半人口受其感染。它被认为是慢性胃炎、消化性溃疡和胃癌的重要致病因素。中性粒细胞在针对幽门螺杆菌的先天防御中起核心作用,但中性粒细胞活化失调会促成上皮损伤和持续炎症。本研究报告,幽门螺杆菌增强中性粒细胞的外泌作用,并刺激释放具有独特生物物理与分子特征的细胞外囊泡。与未感染对照相比,受感染的中性粒细胞释放的囊泡更小、数量更多。这些由幽门螺杆菌诱导的中性粒细胞囊泡(HPN-EVs)在受感染的胃上皮细胞中抑制 PI3K/Akt 信号,增加活性氧,破坏线粒体完整性,并诱导细胞色素 c 释放、caspase 活化与细胞凋亡。蛋白质组学分析显示中性粒细胞颗粒蛋白富集,尤其是 LL-37,而与细胞稳态相关的蛋白减少。由囊泡递送的 LL-37 可再现 HPN-EVs 的关键促凋亡效应,支持其在上皮损伤中的功能作用。与上述结果一致,幽门螺杆菌感染患者的循环囊泡中 LL-37 水平升高,并诱导相似的促凋亡反应。这些结果将富含 LL-37 的 HPN-EVs 确定为中性粒细胞与上皮细胞相互作用的重要介质,并提示研究囊泡相关载荷可作为幽门螺杆菌相关疾病的潜在治疗靶点。
Redox biology IF 16.2 2026-11 PMID: 42731290
Cancer-associated fibroblasts (CAFs) foster an immunosuppressive tumor microenvironment (TME) and confer resistance to immune checkpoint blockade (ICB) in gastric cancer (GC). However, the mechanisms by which specific CAF subsets regulate metabolic crosstalk and immune evasion remain poorly defined. We integrated bulk and single-cell RNA-sequencing data, spatial transcriptomics, and clinical cohorts of GC patients treated with immunotherapy. Functional validation was performed using in vitro co-culture systems, multiple murine models, and lipid nanoparticle (LNP)-encapsulated siRNA targeting Postn. We identified POSTN + CAFs as a key subset enriched in ICB non-responders and associated with poor prognosis. Mechanistically, POSTN secreted by CAFs engaged integrin β1 (ITGB1) on tumor cells and macrophages, activating the PI3K/AKT/mTOR signaling axis and upregulating PPARγ. This signaling cascade drove lipid metabolic reprogramming, characterized by increased lipid accumulation and oxidative stress, and promoted the polarization of macrophages toward an immunosuppressive, lipid-stressed M2 phenotype. Targeting POSTN signaling with LNP-formulated siPostn attenuated tumor growth, suppressed lipid metabolism, and reduced M2 macrophage infiltration in the TME. This work reveals that POSTN + CAFs establish an immunosuppressive TME and are associated with ICB non-response in GC by remodeling lipid metabolism through the ITGB1-PI3K/AKT/mTOR-PPARγ axis, a finding that underscores the therapeutic value of intervening in this specific CAF-macrophage metabolic crosstalk.
中文摘要:癌症相关成纤维细胞(CAFs)在胃癌(GC)中塑造免疫抑制性肿瘤微环境(TME),并导致免疫检查点阻断(ICB)耐药。特定CAF亚群调控代谢串扰与免疫逃逸的机制仍不清楚。我们整合了bulk RNA测序与单细胞RNA测序数据、空间转录组学以及接受免疫治疗的GC患者临床队列。利用体外共培养体系、多种小鼠模型和靶向Postn的脂质纳米颗粒(LNP)包载siRNA进行功能验证。我们发现POSTN+ CAFs是富集于ICB无应答者并与不良预后相关的关键亚群。机制上,CAFs分泌的POSTN与肿瘤细胞和巨噬细胞上的整合素β1(ITGB1)结合,激活PI3K/AKT/mTOR信号轴并上调PPARγ。该信号级联驱动脂质代谢重编程,表现为脂质蓄积和氧化应激增加,并促进巨噬细胞向免疫抑制性、脂质应激的M2表型极化。用LNP配制的siPostn靶向POSTN信号可减弱肿瘤生长、抑制脂质代谢并减少TME中的M2巨噬细胞浸润。该工作揭示,POSTN+ CAFs通过ITGB1-PI3K/AKT/mTOR-PPARγ轴重塑脂质代谢,从而建立免疫抑制性TME并与GC的ICB无应答相关,这一发现凸显了干预该特定CAF-巨噬细胞代谢串扰的治疗价值。
Annals of surgery IF 7.4 2026-11-01 PMID: 42681577
Peritoneal metastases (PMs) represent the most frequent, clinically challenging dissemination pattern in advanced gastric cancer, especially poorly cohesive (PCGC) subtype, and are associated with poor prognosis. We aimed to characterize the transcriptomic landscape of primary gastric tumors (PGTs) and matched PMs to identify differential molecular programs, tumor-microenvironment (TME) features, and potential biomarkers. We analyzed 55 FFPE samples from 23 treatment-naïve patients with synchronous peritoneal-only stage IV PCGC and 10 non-neoplastic gastric controls (NNC). RNA sequencing was analyzed using DESeq2 and GSEA, with cell proportions estimated through immune deconvolution (TIMER/xCell). A total of 4279 differentially expressed genes were identified across all groups. CLDN18 expression progressively decreased from NNCs to PGTs and PMs. Direct PGT-PM comparison revealed that PGTs were characterized by cytoskeletal and extracellular-matrix remodeling genes upregulation, mitotic/cell-cycle, NOTCH and apical-junction pathways enrichment, and memory T-cell predominance. Compared with PGTs, PMs showed increased IGF1, IGFN1, NTRK2 and adipogenesis-related transcripts, adipogenesis and MAPK7/11-NTRK2 signaling enrichment, and macrophage-dominant and dendritic-cell-dominant microenvironments. epithelial-mesenchymal transition (EMT), inflammatory pathways, and cancer-associated fibroblasts were shared by both tumor lesions. PMs did not match established TCGA or PCGC subtypes, suggesting a distinct molecular identity. PMs are characterized by TME remodeling and transcriptional reprogramming. Shared EMT and inflammatory pathways act as bridge linking PGT to PM, consistent with adaptive exploitation of physiological peritoneal programs. Collectively, our findings suggest a transcriptomic framework in which PM can be characterized as a distinct niche-conditioned biological entity and support microenvironment-informed diagnostic and therapeutic strategies.
中文摘要:腹膜转移(PM)是晚期胃癌最常见的、临床上处理困难的播散形式,在低黏附性(PCGC)亚型中尤其突出,预后差。本研究旨在刻画原发胃肿瘤(PGT)与配对腹膜转移灶的转录组图谱,识别差异分子程序、肿瘤微环境(TME)特征与潜在生物标志物。纳入23例初治、同期仅腹膜转移的IV期PCGC患者及10例非肿瘤胃对照(NNC),共分析55份FFPE样本。RNA测序数据以DESeq2与GSEA分析,细胞比例通过免疫解卷积(TIMER/xCell)估计。各组之间共鉴定出4279个差异表达基因。CLDN18表达由NNC至PGT、PM逐步下降。PGT与PM直接比较显示,PGT以细胞骨架与细胞外基质重塑基因上调、有丝分裂/细胞周期、NOTCH及顶端连接通路富集、记忆T细胞占优势为特征;与PGT相比,PM中IGF1、IGFN1、NTRK2及脂肪生成相关转录本升高,脂肪生成与MAPK7/11-NTRK2信号富集,微环境以巨噬细胞与树突状细胞为主。两处肿瘤病灶共享上皮–间质转化(EMT)、炎症通路及癌相关成纤维细胞特征。PM不符合既有的TCGA或PCGC亚型,提示其具有独立的分子身份。PM以TME重塑和转录重编程为特征,共享的EMT与炎症通路把PGT与PM连接起来,与对腹膜生理程序的适应性利用相符。上述结果提示,可将PM视为由生态位决定的独立生物学实体,并为基于微环境的诊断与治疗策略提供依据。
Genes & diseases IF 14.6 2026-11 PMID: 42620747
Human SERHL, a pseudogene-derived lncRNA, plays a key role in cancer progression. However, the mechanism by which SERHL modulates gastric cancer (GC) is mostly unknown. This study found that SERHL was down-regulated in GC and inversely related to its malignancy. Overexpression of SERHL inhibited cell growth and metastasis in GC cells. Mechanistically, SERHL interacts with KLF16, promoting the degradation of KLF16 via ubiquitination in GC cells. The transcription factor KLF16 binds to the promoters of PLCB1 and PRKCA genes, increasing their expression and enhancing GC invasion and metastasis. SERHL reduces motility by inhibiting the KLF16-PLCB1/PRKCA signaling pathway in GC cells. These results highlight the function and mechanism of SERHL in GC progression, indicating that SERHL has the potential to be a diagnostic marker and therapeutic target in GC.
中文摘要:人SERHL是一种由假基因衍生的长链非编码RNA,在肿瘤进展中起关键作用,但其调控胃癌的机制大多尚不清楚。本研究发现SERHL在胃癌中表达下调,且与肿瘤恶性程度呈负相关。过表达SERHL可抑制胃癌细胞的生长与转移。机制上,SERHL与KLF16相互作用,通过泛素化促进胃癌细胞中KLF16的降解。转录因子KLF16结合于PLCB1与PRKCA基因的启动子,提高二者的表达,从而增强胃癌的侵袭与转移。SERHL通过抑制胃癌细胞中的KLF16-PLCB1/PRKCA信号通路降低细胞运动能力。这些结果揭示了SERHL在胃癌进展中的功能与机制,提示SERHL有潜力成为胃癌的诊断标志物与治疗靶点。
Science advances IF 13.9 2026-10-30 PMID: 42962000
Regulatory T cell (Treg) accumulation within the tumor microenvironment is a major contributor to immune evasion and immunotherapy resistance. However, the metabolic signals orchestrating Treg lineage commitment remain poorly defined. We identify that the oxysterol 7α,25-dihydroxycholesterol (7α,25-OHC), produced by Vimentin+ stromal cells, acts through GPR183 to promote Treg differentiation and suppressive identity. In patients with gastric cancer (GC), GPR183+ Treg infiltration correlates with advanced disease and poor survival. In syngeneic tumor models, conditional GPR183 deletion, specifically in CD4+ T cells or Treg cells, demonstrates its cell-intrinsic requirement for high-cholesterol-diet-induced Treg expansion and tumor growth, thereby abrogating immune evasion and restoring CD8+ T cell effector function. Mechanistically, 7α,25-OHC-GPR183 signaling activates the AXL-JAK2-STAT5 pathway to reinforce Foxp3 expression. Last, GPR183 antagonism modestly enhances anti-PD-1 efficacy in a model-dependent manner and prevents therapy-induced Treg expansion. These findings identify the 7α,25-OHC-GPR183-AXL axis as a potential metabolic checkpoint linking cholesterol metabolism to immune suppression, suggesting a potential therapeutic strategy to enhance antitumor immunity.
中文摘要:调节性T细胞(Treg)在肿瘤微环境中积聚,是免疫逃逸和免疫治疗耐药的重要驱动因素。调控Treg谱系定向的代谢信号仍不明确。我们发现,波形蛋白阳性基质细胞产生的氧固醇7α,25-二羟基胆固醇(7α,25-OHC)通过GPR183促进Treg分化和抑制性表型。在胃癌患者中,GPR183阳性Treg浸润与晚期疾病和较差生存相关。在同系肿瘤模型中,于CD4+ T细胞或Treg细胞中条件性敲除GPR183,证明其在细胞内在层面是髙胆固醇饮食诱导Treg扩增和肿瘤生长所必需;敲除GPR183可消除免疫逃逸并恢复CD8+ T细胞效应功能。机制上,7α,25-OHC-GPR183信号激活AXL-JAK2-STAT5通路,增强Foxp3表达。GPR183拮抗以模型依赖的方式适度增强抗PD-1疗效,并阻止治疗诱导的Treg扩增。这些发现将7α,25-OHC-GPR183-AXL轴确定为连接胆固醇代谢与免疫抑制的潜在代谢检查点,提示其可作为增强抗肿瘤免疫的潜在治疗策略。

2胃癌 (5篇)

临床研究 (3篇)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2026-11-05 PMID: 42986510
Familial predisposition accounts for around 10% of gastric cancers (GC), and 1-3% are linked to germline pathogenic variants (GPVs) in known high-penetrance GC predisposition genes. However, comprehensive analyses of hereditary GC remain limited, as current strategies remain largely centered on CDH1-associated hereditary diffuse gastric cancer. We aimed to assess the contribution of GPVs in CDH1 and other cancer predisposing genes (CPGs) to familial and early-onset GC. We applied five expanded clinical criteria to identify patients at risk for hereditary GC. Genetic testing was performed in 115 patients with intestinal, diffuse, or mixed gastric cancer using multigene panels containing 26-113 CPGs. GPVs were identified in 15.7% of patients, including CDH1 (4.3%), MUTYH monoallelic (4.3%), TP53 (3.5%-all were the p.Arg337His founder variant), ATM (1.7%), and CHEK2 and MLH1 (0.9% each). Additionally, 6% of patients had prioritized variants of uncertain significance. We compared the prevalence of MUTYH p.Gly396Asp and p.Tyr179Cys in the full GC cohort (290 patients) with a Brazilian control population (OR: 2.2; 95% CI 0.96-4.93; p = 0.06). Patients with tumors located in the distal esophagus or cardia showed a higher frequency of GPVs (38.9%) than those with tumors in other sites (12.4%) (p = 0.01). GPVs did not significantly impact other clinical features. In this exploratory Brazilian cohort, multigene testing revealed a heterogeneous spectrum of GPVs beyond CDH1, including the recurrent TP53 p.Arg337His founder variant, highlighting the value of comprehensive oncogenetic assessment and population-specific context when considering germline testing.
中文摘要:家族易感性约占胃癌的10%,其中1-3%与已知高外显率胃癌易感基因的胚系致病变异(GPVs)相关。现有策略仍主要围绕CDH1相关遗传性弥漫型胃癌,遗传性胃癌的综合分析有限。本研究旨在评估CDH1及其他癌症易感基因(CPGs)的GPVs对家族性和早发性胃癌的贡献。采用五项扩展临床标准识别遗传性胃癌风险患者。对115例肠型、弥漫型或混合型胃癌患者使用包含26-113个CPGs的多基因检测组合进行基因检测。15.7%患者检出GPVs,包括CDH1(4.3%)、MUTYH单等位(4.3%)、TP53(3.5%,均为p.Arg337His奠基者变异)、ATM(1.7%)、CHEK2和MLH1(各0.9%)。另有6%患者存在优先关注的意义未明变异。比较全部胃癌队列(290例)与巴西对照人群中MUTYH p.Gly396Asp和p.Tyr179Cys的患病率(OR 2.2;95% CI 0.96-4.93;p=0.06)。肿瘤位于远端食管或贲门者GPVs频率(38.9%)高于其他部位(12.4%)(p=0.01)。GPVs未显著影响其他临床特征。在这个探索性巴西队列中,多基因检测揭示了CDH1之外异质性的GPVs谱,包括反复出现的TP53 p.Arg337His奠基者变异,提示在考虑胚系检测时全面肿瘤遗传学评估和人群特异性背景的价值。
MedComm IF 14.1 2026-11 PMID: 42959646
Gastric cancer is a multifactorial disease shaped by diverse risk factors and a complex pathogenesis spanning from chronic atrophic gastritis to invasive malignancy. Its global incidence shows marked geographic disparities, and advances in understanding its pathogenic mechanisms have improved diagnosis and treatment. Although the relationship between gastric cancer and macrophages has been extensively investigated, a systematic review integrating the entire clinical and biological continuum of gastric cancer, from epidemiology to management, with a focus on macrophages remains lacking. This review summarizes the epidemiology and multidimensional risk factors for gastric cancer, including infectious, dietary, genetic, microbiome, and metabolite-related factors. We describe the evolution of precancerous conditions, molecular alterations such as miRNA expression, and the bidirectional interactions between gastric cancer cells and macrophages that drive tumor progression within the tumor microenvironment. We also review clinical features, diagnostic approaches based on screening and endoscopy, and current management strategies, including surgery, systemic therapies, targeted therapies, immunotherapy, macrophage-targeted therapies, macrophage metabolic reprogramming, and recent preclinical and clinical advances. Overall, this review integrates evidence from epidemiology, molecular biology, immunology, and pathology to provide a comprehensive framework for understanding gastric cancer pathogenesis and current as well as emerging therapeutic strategies.
中文摘要:胃癌是一种受多种危险因素影响的多因素疾病,其发病机制复杂,可从慢性萎缩性胃炎进展至浸润性恶性肿瘤。全球发病率存在明显地域差异,对发病机制认识的进步改善了诊断与治疗。胃癌与巨噬细胞的关系已得到广泛研究,但仍缺乏聚焦巨噬细胞、整合胃癌从流行病学到管理整个临床与生物学连续体的系统综述。本综述总结胃癌的流行病学及多维危险因素,包括感染、饮食、遗传、微生物组和代谢物相关因素。文章描述癌前病变的演变、miRNA表达等分子改变,以及胃癌细胞与巨噬细胞在肿瘤微环境中驱动肿瘤进展的双向相互作用。本综述还回顾临床特征、基于筛查和内镜的诊断方法,以及当前管理策略,包括手术、全身治疗、靶向治疗、免疫治疗、巨噬细胞靶向治疗、巨噬细胞代谢重编程,以及近期临床前和临床进展。该综述整合流行病学、分子生物学、免疫学和病理学证据,为理解胃癌发病机制及当前和新兴治疗策略提供综合框架。
Cancer letters IF 11.8 2026-11-01 PMID: 42674310
Gastric cancer (GC) ranks as the fifth most common cancer worldwide, however, accurate and non-invasive diagnostic modalities for GC remain limited. Cell-free DNA (cfDNA) fragmentomics has emerged as a promising tool for cancer cell detection. Here we develop a gastric cancer detection model, named GaFraD model. The GaFraD model uses four cfDNA fragmentomics features, including fragment size ratio (FSR), copy number variation (CNV), 9-bp end motif (Motif), and fragment size at transcription start sites (TF). This model achieves an area under the receiver-operating characteristic curve (AUC) of 0.970 (95% CI: 0.944 - 0.990), a sensitivity of 95.0% and a specificity of 80.9%. By combining the GaFraD model and conventional protein biomarkers CA19-9 and PG-I/PG-II, the CONFIRM model was generated. The CONFIRM model attained an AUC of 0.986 (95% CI: 0.966 - 1.000), a sensitivity of 95.0% and a specificity of 95.6% in detecting GC. Moreover, the CONFIRM model achieved remarkable performance (AUC = 0.983, sensitivity 95.6%, specificity 94.2%) in distinguishing patients with early-stage GC from controls. Our work showed the high discriminatory power in distinguishing GC patients from controls, indicating the clinical potential of using cfDNA fragmentomics combined with protein biomarkers for non-invasive GC detection. The results of the study provide a new avenue for early, accurate, and non-invasive clinical diagnosis of GC.
中文摘要:胃癌(GC)是全球第五大常见癌症,然而准确且无创的GC诊断手段仍有限。游离DNA(cfDNA)片段组学已成为检测癌细胞的有前景工具。本研究开发了一种胃癌检测模型,命名为GaFraD模型。GaFraD模型使用四种cfDNA片段组学特征,包括片段大小比值(FSR)、拷贝数变异(CNV)、9-bp末端基序(Motif)以及转录起始位点处的片段大小(TF)。该模型的受试者工作特征曲线下面积(AUC)为0.970(95% CI:0.944 - 0.990),灵敏度为95.0%,特异度为80.9%。将GaFraD模型与常规蛋白标志物CA19-9和PG-I/PG-II结合,构建了CONFIRM模型。CONFIRM模型在检测GC时AUC为0.986(95% CI:0.966 - 1.000),灵敏度为95.0%,特异度为95.6%。CONFIRM模型在区分早期GC患者与对照者方面表现突出(AUC=0.983,灵敏度95.6%,特异度94.2%)。本工作显示其在区分GC患者与对照者方面具有较高判别能力,表明cfDNA片段组学联合蛋白标志物用于无创GC检测具有临床潜力。研究结果为GC的早期、准确、无创临床诊断提供了新途径。

基础研究 (2篇)

Cancer letters IF 11.8 2026-11-01 PMID: 42710828
Recurrence and peritoneal metastasis remain major challenges in gastric cancer (GC), highlighting the need to identify actionable stromal-tumor signaling circuits within the tumor microenvironment (TME). Integrated transcriptomic analyses and clinical validation identified TAGLN as a fibroblast-enriched factor associated with GC progression and poor prognosis. Functional studies showed that TAGLN expression in cancer-associated fibroblasts (CAFs) enhanced HGF production, at least in part through NF-κB activation, thereby promoting GC-cell malignant phenotypes via paracrine HGF/c-MET signaling. Mechanistically, HGF/c-MET activation promoted DDX5 phosphorylation, with Tyr595 identified as a critical phosphorylation site, and increased DDX5 nuclear accumulation. Nuclear DDX5 was enriched at the CAV1 promoter and enhanced CAV1 transcription, whereas CAV1 promoted malignant phenotypes by activating the PI3K/AKT/mTOR signaling. Salvianolic acid A (SA-A) showed TAGLN target engagement in DARTS and CETSA assays and attenuated TAGLN-associated CAF activity. In vivo, SA-A suppressed CAF-driven tumor growth and peritoneal dissemination. Collectively, these findings define a CAF-TAGLN/HGF/c-MET/DDX5/CAV1 signaling cascade linking stromal activation to tumor-cell transcriptional reprogramming and CAF-tumor crosstalk within the TME, and identify TAGLN as a potential therapeutic vulnerability for microenvironment-directed intervention in GC.
中文摘要:复发和腹膜转移仍是胃癌(GC)的主要难题,肿瘤微环境(TME)中可干预的基质-肿瘤信号环路因此成为需要识别的目标。整合转录组分析与临床验证显示,TAGLN是一种富集于成纤维细胞的因子,与GC进展和不良预后相关。功能研究显示,癌症相关成纤维细胞(CAF)中的TAGLN表达增强HGF产生,至少部分通过NF-κB激活实现,并经旁分泌HGF/c-MET信号促进GC细胞恶性表型。机制上,HGF/c-MET激活促进DDX5磷酸化,Tyr595被鉴定为关键磷酸化位点,并增加DDX5核内积聚。核内DDX5富集于CAV1启动子并增强CAV1转录,CAV1则通过激活PI3K/AKT/mTOR信号促进恶性表型。丹酚酸A(SA-A)在DARTS和CETSA实验中显示可与TAGLN靶点结合,并减弱TAGLN相关CAF活性。体内实验中,SA-A抑制CAF驱动的肿瘤生长和腹膜播散。上述发现定义了一条CAF-TAGLN/HGF/c-MET/DDX5/CAV1信号级联,将基质激活与肿瘤细胞转录重编程及TME内CAF-肿瘤串扰联系起来,并将TAGLN识别为GC微环境导向干预的潜在治疗脆弱点。
Genes & diseases IF 14.6 2026-11 PMID: 42633192
psiTPTE22-HERV is a human-specific gene with unexplored functions. This study investigated its regulation, molecular mechanism, and clinical significance in gastric cancer. psiTPTE22-HERV expression was consistently down-regulated in primary tumors and cancer cell lines across various cancer types, including gastric cancer, as indicated by TCGA data and quantitative PCR analysis. Its down-regulation in gastric cancer cells is mediated by promoter methylation, confirmed through bisulfite genomic sequencing, with expression restored following demethylation treatment. A progressive reduction in psiTPTE22-HERV expression was observed from normal stomach mucosa to adjacent non-tumor tissues and primary tumors, along with increased methylation. psiTPTE22-HERV inhibited cancer cell viability, clonogenicity, cell cycle progression, migration, and invasion while promoting apoptosis. It also suppressed subcutaneous tumor growth and distant metastasis in mice. Transcriptomic analysis revealed that psiTPTE22-HERV disrupted PI3K/AKT/mTOR signaling. Western blotting confirmed that psiTPTE22-HERV reduced protein levels of PI3K, p-AKT, and mTOR. This led to the down-regulation of EIF4E and EIF4EBP1, oncogenic protein synthesis genes and effectors of mTOR signaling, as well as p-EIF4EBP1(Thr70), which is regulated by mTOR. Notably, psiTPTE22-HERV expression was inversely correlated with EIF4E, EIF4EBP1, and p-EIF4EBP1 (Thr70) in gastric tumors (all P < 0.001). Multivariate analysis revealed that psiTPTE22-HERV expression in primary gastric tumors independently predicted survival (P = 0.027). Kaplan-Meier survival analysis showed that low psiTPTE22-HERV expression was associated with shortened survival in gastric cancer patients (P = 0.0009). Overall, psiTPTE22-HERV plays a tumor-suppressive role by inhibiting the PI3K/AKT/mTOR/EIF4E pathway, and its down-regulation serves as an independent marker for poor prognosis in gastric cancer patients.
中文摘要:psiTPTE22-HERV是一个人类特异性基因,其功能尚未阐明。本研究探讨了该基因在胃癌中的调控、分子机制及临床意义。TCGA数据和定量PCR分析显示,psiTPTE22-HERV在包括胃癌在内的多种癌症的原发肿瘤和癌细胞系中均持续下调。亚硫酸氢盐基因组测序证实,其在胃癌细胞中的下调由启动子甲基化介导,去甲基化处理后表达恢复。从正常胃黏膜到癌旁非肿瘤组织再到原发肿瘤,psiTPTE22-HERV表达呈进行性降低,同时甲基化水平升高。psiTPTE22-HERV抑制癌细胞活力、克隆形成、细胞周期进展、迁移和侵袭,并促进凋亡。它还可抑制小鼠皮下肿瘤生长和远处转移。转录组分析显示,psiTPTE22-HERV干扰PI3K/AKT/mTOR信号通路。蛋白印迹实验证实,psiTPTE22-HERV降低PI3K、p-AKT和mTOR蛋白水平。这导致EIF4E和EIF4EBP1下调;二者是致癌蛋白合成基因,也是mTOR信号通路的效应分子;受mTOR调控的p-EIF4EBP1(Thr70)也下调。在胃肿瘤中,psiTPTE22-HERV表达与EIF4E、EIF4EBP1及p-EIF4EBP1(Thr70)呈负相关(均P < 0.001)。多因素分析显示,原发胃肿瘤中psiTPTE22-HERV表达可独立预测生存(P = 0.027)。Kaplan-Meier生存分析显示,psiTPTE22-HERV低表达与胃癌患者生存期缩短相关(P = 0.0009)。总体而言,psiTPTE22-HERV通过抑制PI3K/AKT/mTOR/EIF4E通路发挥抑癌作用,其下调可作为胃癌患者不良预后的独立标志物。

3减重/代谢手术 (5篇)

临床研究 (5篇)

MedComm IF 14.1 2026-11 PMID: 42985237
Suboptimal clinical response (SCR) after sleeve gastrectomy (SG) remains a major clinical challenge, yet reliable preoperative risk stratification is lacking. Therefore, we developed and externally validated an interpretable machine-learning model for predicting SCR after SG using multicenter data from three tertiary hospitals in China. Overall, 1312 patients were included, comprising a derivation cohort (n = 1094) and two external validation cohorts (n = 84 and n = 134). SCR, defined as percentage of total weight loss < 25% at 1 year, occurred in 374 (34.2%), 34 (40.5%), and 45 (33.6%) patients, respectively. Among six machine-learning algorithms, XGB achieved the best performance. The final model incorporated eight routinely available predictors. In internal validation, the model showed excellent discrimination, with an AUC of 0.821 (95% confidence interval [CI], 0.752-0.871), sensitivity of 0.803, and specificity of 0.714. External validation confirmed satisfactory discrimination (AUC 0.761; 95% CI, 0.688-0.823), good calibration, and clinical benefit. Notably, the XGB model significantly outperformed 10 clinicians across experience levels and remained superior in clinically challenging cases. SHAP analysis enhanced interpretability, with predictor importance ranked as BMI, age, fasting glucose, type 2 diabetes, vitamin B12, calcium, total cholesterol, and gamma-glutamyl transferase. This interpretable XGB model may enable precise preoperative risk stratification and support personalized management for patients undergoing SG.
中文摘要:袖状胃切除术(SG)后出现次优临床反应(SCR)仍是临床难题,术前可靠的风险分层手段尚缺乏。为此,我们利用中国三家三级医院的多中心数据,构建并外部验证了一个可解释的机器学习模型,用于预测SG术后SCR。共纳入1312例患者,含推导队列(n=1094)与两个外部验证队列(n=84和n=134)。SCR定义为术后1年总体重减少百分比<25%,三个队列中分别有374例(34.2%)、34例(40.5%)和45例(33.6%)出现SCR。六种机器学习算法中XGB表现最佳,最终模型纳入8个常规可获得的预测变量。内部验证区分度良好,AUC为0.821(95%置信区间0.752–0.871),敏感度0.803,特异度0.714。外部验证证实区分度满意(AUC 0.761;95%置信区间0.688–0.823),校准良好且具临床获益。XGB模型的表现显著优于不同经验层次的10位临床医师,在临床疑难病例中依然占优。SHAP分析提升了模型可解释性,预测变量重要性依次为BMI、年龄、空腹血糖、2型糖尿病、维生素B12、钙、总胆固醇和γ-谷氨酰转移酶。该可解释XGB模型或可支持精准的术前风险分层,为接受SG的患者提供个体化管理依据。
Annals of surgery IF 7.4 2026-11-03 PMID: 42972633
To evaluate 2-year weight loss after bariatric surgery among adults with intolerable adverse effects or inadequate weight loss with semaglutide or tirzepatide. Semaglutide and tirzepatide are effective obesity medications, but intolerance and inadequate weight loss are common, creating uncertainty about next-step therapy. This retrospective cohort included adults with BMI ≥35 kg/m² undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) at Cleveland Clinic hospitals from 2018 to 2024. Electronic health record and dispensing data classified preoperative semaglutide or tirzepatide exposure and response. The primary outcome was estimated 2-year total body weight loss (TBWL), stratified by procedure and type 2 diabetes (T2DM) status. Among 4929 patients, 4661 had no prior exposure (comparator group), 61 discontinued semaglutide or tirzepatide because of intolerable adverse effects, and 207 had inadequate weight-loss response. Before surgery, estimated 2-year medication-associated weight change was a 1.4% gain in the intolerance group and 1.5% TBWL in the inadequate-response group. After surgery, 2-year TBWL in the intolerance group was 27.9% and 22.7% after RYGB and 20.1% and 21.6% after SG among patients without and with T2DM, respectively. Corresponding estimates in the inadequate-response group were 35.8%, 27.4%, 14.3%, and 14.2%. For comparison, corresponding 2-year TBWL estimates in the comparator group were 33.3%, 28.7%, 23.6%, and 19.9%. In adjusted analysis of the inadequate-response group, RYGB was associated with greater 2-year TBWL than SG (32.7% vs. 17.8%; difference, 14.9 percentage points [95% CI, 13.1%-16.7%]). Bariatric surgery was associated with clinically meaningful 2-year weight loss after semaglutide or tirzepatide intolerance or inadequate response, with RYGB potentially offering greater benefit after inadequate response.
中文摘要:评估在接受司美格鲁肽或替尔泊肽治疗时出现无法耐受的不良反应或减重不足的成人中,减重手术后2年体重下降情况。司美格鲁肽和替尔泊肽是有效的减重药物,但耐受性差和减重不足常见,使下一步治疗存在不确定性。这项回顾性队列纳入2018至2024年在克利夫兰诊所医院接受Roux-en-Y胃旁路术(RYGB)或袖状胃切除术(SG)且BMI≥35 kg/m²的成人。通过电子健康记录和配药数据判定术前司美格鲁肽或替尔泊肽暴露及反应。主要结局为估计的2年总体重下降百分比(TBWL),按术式和2型糖尿病(T2DM)状态分层。在4929例患者中,4661例既往无暴露(对照组),61例因无法耐受的不良反应停用司美格鲁肽或替尔泊肽,207例减重反应不足。术前,估计的2年药物相关体重变化在不能耐受组为增加1.4%,在反应不足组为TBWL 1.5%。术后,不能耐受组无T2DM和有T2DM患者接受RYGB后的2年TBWL分别为27.9%和22.7%,接受SG后分别为20.1%和21.6%。反应不足组的相应估计值分别为35.8%、27.4%、14.3%和14.2%。作为对照,对照组相应的2年TBWL估计值分别为33.3%、28.7%、23.6%和19.9%。在反应不足组的校正分析中,RYGB与SG相比2年TBWL更高(32.7%对17.8%;差值14.9个百分点[95% CI,13.1%-16.7%])。在司美格鲁肽或替尔泊肽不能耐受或反应不足后,减重手术与有临床意义的2年体重下降相关,反应不足后RYGB可能带来更大获益。
Annals of surgery IF 7.4 2026-11-02 PMID: 42969414
To evaluate histologic cirrhosis regression after metabolic bariatric surgery (MBS) in patients with compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. Cirrhosis in MASH has traditionally been considered irreversible. Although MBS improves steatohepatitis and fibrosis in noncirrhotic MASH, its impact on established cirrhosis remains uncertain. This retrospective study included adults with biopsy-proven compensated MASH cirrhosis who underwent MBS at Cleveland Clinic from 2004 to 2024 and had paired baseline and follow-up liver biopsies. The primary outcome was regression from NASH Clinical Research Network (NASH CRN) stage 4 to stage 3 or lower. Fibrosis was also assessed using modified Ishak staging and the Beijing classification. Thirty patients were included; 22 (73%) were female, median age was 54.2 years, and median baseline body mass index was 43.7 kg/m². The median (IQR) biopsy interval was 6.2 (2.0-9.2) years, median body weight reduction was 31.8 (21.4-40.4) kg, and median total weight loss was 23.9% (18.0%-30.5%). Cirrhosis regression occurred in 33% of patients using NASH CRN staging and in 40% using modified Ishak staging. Regressive fibrosis features were identified in 60% of patients using the Beijing classification. Significant improvements were also observed in steatosis, lobular inflammation, and hepatocyte ballooning. MBS was associated with histologic cirrhosis regression in a substantial proportion of patients with biopsy-proven compensated MASH cirrhosis. More detailed histologic frameworks identified additional fibrosis improvement and regressive remodeling, suggesting that compensated MASH cirrhosis may be reversible after sustained metabolic intervention.
中文摘要:评估代谢减重手术(MBS)后代偿性代谢功能障碍相关脂肪性肝炎(MASH)肝硬化患者的组织学肝硬化逆转。MASH相关肝硬化传统上被视为不可逆。MBS可改善非肝硬化MASH的脂肪性肝炎和纤维化,但对已形成的肝硬化影响仍不确定。这项回顾性研究纳入2004至2024年在Cleveland Clinic接受MBS、经活检证实为代偿性MASH肝硬化且有基线与随访配对肝活检的成人。主要结局为从NASH临床研究网络(NASH CRN)4期逆转至3期或更低。纤维化还采用改良Ishak分期和Beijing分类评估。共纳入30例患者,22例(73%)为女性,中位年龄54.2岁,中位基线体重指数43.7 kg/m²。中位(IQR)活检间隔6.2(2.0-9.2)年,中位体重减少31.8(21.4-40.4)kg,中位总体重下降23.9%(18.0%-30.5%)。按NASH CRN分期,33%的患者出现肝硬化逆转;按改良Ishak分期,40%出现肝硬化逆转。按Beijing分类,60%的患者可见纤维化逆转特征。脂肪变、小叶炎症和肝细胞气球样变也观察到显著改善。在经活检证实的代偿性MASH肝硬化患者中,相当比例在MBS后出现组织学肝硬化逆转。更细致的组织学框架识别出额外的纤维化改善和逆转性重塑,提示代偿性MASH肝硬化在持续代谢干预后可能可逆。
MedComm IF 14.1 2026-11 PMID: 42959411
Current guidelines support bariatric surgery (BS) as an effective treatment mainly for patients with severe obesity and poorly controlled hypertension. However, evidence in non-severely obese Asian populations remains limited. This multicenter prospective cohort study included 248 Chinese patients with obesity and hypertension who underwent BS between 2010 and 2019 and were followed for up to 10 years. An exploratory mechanistic substudy (n = 14) evaluated 24-h ambulatory blood pressure (BP), various biomarkers, and urinary electrolytes before and after BS. Compared with baseline, adjusted mean systolic blood pressure (SBP) was lower by 16.4, 14.8, 15.1, 18.0, and 15.2 mmHg, while diastolic blood pressure (DBP) decreased by 11.4, 9.1, 9.9, 10.5, and 11.4 mmHg at 3 months, 6 months, and 1, 5, 10 years postoperatively. During postoperative Days 1 to 7 (POD1-7), mean SBP and DBP dropped by 8.6 and 10.4 mmHg, and the proportion achieving BP < 140/90 mmHg increased to 62.9% and remained at 70.8% even 10 years later. The substudy has observed that early BP reduction was accompanied by increased electrolytes and water excretion, as well as a transient suppression of renin-angiotensin-aldosterone system (RAAS)-related biomarkers, providing a direction for future in-depth exploration. These findings suggest that BS in Chinese patients was followed by rapid BP reductions, with lower BP observed among the smaller subsets assessed longer term, including those without severe obesity. Trial Registration: NCT07183137.
中文摘要:现行指南支持将减重手术作为主要针对重度肥胖且血压控制不佳患者的有效治疗,但非重度肥胖亚洲人群中的证据仍有限。这项多中心前瞻性队列研究纳入248例2010年至2019年接受减重手术的中国肥胖合并高血压患者,随访最长10年。一项探索性机制亚组(n=14)评估了减重手术前后的24小时动态血压、多种生物标志物及尿电解质。与基线相比,校正后平均收缩压(SBP)在术后3个月、6个月及1年、5年、10年分别降低16.4、14.8、15.1、18.0、15.2 mmHg,舒张压(DBP)分别降低11.4、9.1、9.9、10.5、11.4 mmHg。术后第1至7天,平均SBP和DBP分别下降8.6和10.4 mmHg,血压低于140/90 mmHg者比例增至62.9%,即使10年后仍保持在70.8%。该亚组观察到,早期血压下降伴随电解质和水排泄增加,以及肾素-血管紧张素-醛固酮系统(RAAS)相关生物标志物的短暂抑制,为后续深入探索提供了方向。这些结果提示,中国患者接受减重手术后血压快速下降,在随访时间较长、样本量较小的亚组中也观察到血压降低,包括非重度肥胖者。试验注册号:NCT07183137。
Journal of obesity & metabolic syndrome IF 12.7 2026-10-30 PMID: 42843854
Obesity remains a growing global health crisis, affecting nearly one billion adults worldwide and substantially increasing the risk of cardiometabolic disease, malignancy, and premature mortality. Metabolic and bariatric surgery (MBS) has evolved into an effective and durable treatment for severe obesity, providing sustained weight loss and significant remission of obesity-related comorbidities (i.e., type 2 diabetes mellitus and cardiovascular disease). Despite dramatic improvements in safety, efficacy, and long-term outcomes over time, MBS remains markedly underutilized, reaching fewer than 1% of eligible patients. Persistent barriers include limited patient and provider awareness, misconceptions regarding surgical risk, and significant disparities in access to care. Concurrently, the rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has transformed the medical management of obesity, offering effective pharmacologic weight loss but raising questions regarding their impact on MBS utilization, durability, and cost-effectiveness. Emerging evidence demonstrates that while MBS produces greater and more durable weight loss than GLP-1 RAs alone, these therapies need not be competitive. Rather, GLP-1 RAs may serve as 'neoadjuvant' treatment to optimize surgical candidacy or as adjunctive treatment for inadequate weight loss or postoperative weight regain. This review synthesizes contemporary data on MBS procedures, outcomes, disparities in access, and evolving perceptions of obesity treatment in the GLP-1 RA era. We propose a chronic weight management model that integrates pharmacotherapy, surgery, and multidisciplinary care along a continuous treatment spectrum. Positioning MBS and GLP-1 RAs as complementary modalities within individualized care pathways may improve long-term outcomes, expand access, and better address the complex, chronic nature of obesity.
中文摘要:肥胖仍是不断加剧的全球健康危机,影响全球近十亿成年人,并显著增加心血管代谢疾病、恶性肿瘤和过早死亡的风险。代谢与减重手术(MBS)已发展为治疗重度肥胖的有效且持久的手段,可带来持续减重,并使肥胖相关合并症(如2型糖尿病和心血管疾病)获得显著缓解。尽管安全性、疗效和长期结局不断改善,MBS仍明显未被充分利用,仅覆盖不足1%的符合条件的患者。持续存在的障碍包括患者和提供者认知有限、对手术风险的误解以及获得医疗资源方面的显著差异。与此同时,胰高血糖素样肽-1受体激动剂(GLP-1 RAs)的快速应用改变了肥胖的药物治疗格局,可有效实现药物减重,但也引发对其对MBS使用率、持久性和成本效果影响的疑问。新出现的证据显示,MBS带来的减重幅度和持久性优于单用GLP-1 RAs,但两类治疗不必相互竞争。GLP-1 RAs可作为「新辅助」治疗以优化手术候选资格,或作为减重不足或术后体重反弹的辅助治疗。本综述整合了关于MBS术式、结局、获取差异以及GLP-1 RA时代肥胖治疗观念演变的最新数据。我们提出一种慢性体重管理模型,在连续治疗谱系中整合药物治疗、手术和多学科照护。将MBS与GLP-1 RAs定位为个体化照护路径中的互补手段,可能改善长期结局、扩大可及性,并更好地应对肥胖复杂、慢性的本质。

4食管癌/食管切除 (3篇)

临床研究 (3篇)

Annals of surgery IF 7.4 2026-11-01 PMID: 42816873
Robotic-assisted minimally invasive esophagectomy (RAMIE) has significantly improved the quality of surgery, reflecting in better functional outcomes, faster recovery, less postoperative morbidity, and even improved oncological results in patients with locally advanced cancer of the esophagus compared with an open approach. The IDEAL (idea, development, exploration, assessment, long-term study) Framework provides a structured, staged approach to evaluating surgical innovations. The Stage 1 studies describe the introduction of this technique published in 2003 and 2006 as a proof of concept already showing an acceptable benchmarking for early implementation (48% pulmonary complication rate, 5% mortality). The Stage 2 Exploration phase followed, showing oncological long-term follow-up with 48% 5-year survival rates. The Stage 3 trials (i.e., ROBOT Trial) have proven RAMIE to not only be equivalent, but significantly superior for overall complications, pain scores, and quality of life compared with an open approach. Long-term follow-up revealed no differences in survival, making RAMIE oncologically equivalent at a minimum. The Stage 4 evaluation phase started in 2017 with the foundation of the Upper GI International Robotic Association (UGIRA) global registry, which as of November 2025 has 58 contributing sites worldwide and collected 5567 RAMIE cases. With textbook outcome of 41%-61%, contemporary leak rates of 11%-16% in the most recent UGIRA cohort depending on technique and mortality <4%, RAMIE was safely implemented and is increasingly becoming the primary technique of choice at high-volume tertiary centers. The foundation of the international UGIRA registry has provided compelling evidence regarding standardized training pathways and guidelines and already serves as a scientific template for future technical evolution in upper GI surgery.
中文摘要:与开放手术相比,机器人辅助微创食管切除术(RAMIE)显著提高了手术质量,体现为功能结局更好、恢复更快、术后并发症更少,甚至使局部晚期食管癌患者获得更好的肿瘤学结果。IDEAL(设想、开发、探索、评估、长期研究)框架为外科创新提供结构化、分阶段的评价方法。第1阶段研究描述了该技术于2003年和2006年发表的引入情况,作为概念验证已显示早期实施具有可接受的基准(肺部并发症率48%,死亡率5%)。随后进入第2阶段探索期,肿瘤学长期随访显示5年生存率为48%。第3阶段试验(即ROBOT试验)证明,与开放手术相比,RAMIE不仅等效,而且在总体并发症、疼痛评分和生活质量方面显著更优。长期随访未发现生存差异,至少说明RAMIE在肿瘤学上等效。第4阶段评估期始于2017年,以上消化道国际机器人协会(UGIRA)全球注册数据库的建立为标志;截至2025年11月,该数据库已有全球58个贡献中心,收集5567例RAMIE病例。在最近UGIRA队列中,教科书式结局为41%-61%,当前吻合口漏率为11%-16%(取决于技术),死亡率低于4%;RAMIE得到安全实施,并日益成为高容量三级中心的首选技术。国际UGIRA注册数据库的建立为标准化培训路径和指南提供了有力证据,并已成为上消化道外科未来技术演进的科学模板。
Annals of surgery IF 7.4 2026-11-01 PMID: 42687130
To determine the impact of severity of esophageal anastomotic leak (AL), standardized by ECCG grading, on long-term survival within a contemporary multicenter cohort. Historical evidence suggesting AL is associated with increased recurrence and poor survival is limited by heterogeneous definitions and outdated management. This study utilizes the standardized ECCG definition to evaluate the prognostic significance of AL severity under modern perioperative protocols and endoscopic rescue strategies. An international multicenter cohort across 17 high-volume European centers. Adult patients with esophageal or junctional cancer treated with neoadjuvant CROSS or FLOT, followed by esophagectomy were included (2018-2023). Out of 2905 patients, 425 (14.6%) developed an AL. AL was associated with a nearly two-fold increase in pulmonary complications (46.8% vs. 26.7%; P <0.001). AL requiring surgical reintervention (type III) was associated with an increased 30- and 90-days mortality rate (7.3% vs. 2.7% and 12.3% vs. 4%, P <0.001) and a significant reduction in median overall survival versus the no leak group (33.9 vs. 69.3; months P <0.001). After multivariable adjustment, type III AL was associated with a greater likelihood of death (HR 1.51; 95% CI: 1.04-2.18; P =0.029). A lower rate of adjuvant therapy administration (33.9% vs. 43.3%; P =0.004) was observe for AL patients. No significant survival deficits were observed for leaks treated conservatively or with no-surgical intervention. AL requiring surgical reintervention was associated with impaired survival. This relationship identifies a high-risk clinical profile and represents a critical target for future research into strategies for clinical stabilization and risk mitigation.
中文摘要:旨在明确按ECCG分级标准化的食管吻合口漏(AL)严重程度对当代多中心队列长期生存的影响。既往证据提示AL与复发增加和生存不良相关,但受定义异质性和诊疗方式过时限制。采用ECCG标准化定义,评估在现代围手术期方案和内镜挽救策略下AL严重程度的预后意义。研究纳入17家欧洲高容量中心组成的国际多中心队列,2018—2023年接受新辅助CROSS或FLOT方案后行食管切除术的食管癌或交界部癌成年患者。2905例患者中425例(14.6%)发生AL。AL与肺部并发症增加近两倍相关(46.8% vs. 26.7%;P <0.001)。需要外科再干预的AL(III型)与30天和90天死亡率升高相关(7.3% vs. 2.7%和12.3% vs. 4%;P <0.001),并与无漏组相比中位总生存期显著缩短(33.9个月 vs. 69.3个月;P <0.001)。多变量校正后,III型AL与死亡可能性增加相关(HR 1.51;95% CI:1.04—2.18;P =0.029)。AL患者接受辅助治疗的比例较低(33.9% vs. 43.3%;P =0.004)。接受保守治疗或未接受外科干预的漏患者未观察到显著生存劣势。需要外科再干预的AL与生存受损相关。这一关系识别出高风险临床特征,并为未来研究临床稳定化和风险减轻策略提供了关键目标。
Annals of surgery IF 7.4 2026-11-01 PMID: 42613668
Assess the incidence and management of intraoperative adverse events (IAEs) during robot-assisted minimally invasive esophagectomy (RAMIE) and evaluate their impact on postoperative outcomes. IAEs are an inherent component of surgical practice and owing to its complexity, esophagectomy is no exception. Data on their incidence and management remain limited. Robotic assistance may facilitate management of these events. This retrospective observational cohort study analyzed prospectively collected data from consecutive RAMIE performed at UMC Utrecht using the da Vinci Xi system. iAEs were categorized using the ClassIntra classification. Perioperative outcomes were compared according to major IAEs occurrence (ClassIntra ≥III). Between 2018 and 2025, 478 RAMIE were performed. IAEs occurred in 41 patients (8.6%; 46 events), of which 92.7% were managed robotically without conversion. Bleeding was the most common event (69.6%), followed by chyle leaks (8.7%), lung injuries (8.7%), and airway injuries (4.3%). Major IAEs occurred in 20 patients (4.2%) and were associated with increased mean blood loss (1211 vs. 296 mL, P <0.001), higher conversion rates (15.0% vs. 1.3%, P =0.005) and longer mean operative time (478.6 vs. 413.3 min, P =0.022). Major postoperative complications (35.0% vs. 37.3%, P =1.000), median hospital length of stay (11 vs. 11 d, P =0.311) and in-hospital mortality (5.0% vs. 2.7%, P =0.446) were comparable between groups. In this retrospective cohort, over 90% of IAEs during RAMIE were managed robotically without conversion, with no significant increase in postoperative morbidity. These results should be interpreted in the context of an expert center and a limited number of events.
中文摘要:评估机器人辅助微创食管切除术(RAMIE)术中不良事件(IAEs)的发生率与处理方式,并评价其对术后结局的影响。IAEs是外科实践固有的一部分,食管切除术因其复杂性也不例外。有关其发生率与处理的数据仍有限。机器人辅助可能有助于处理这些事件。这项回顾性观察性队列研究分析了UMC Utrecht连续开展的使用da Vinci Xi系统的RAMIE前瞻性收集数据。IAEs按ClassIntra分类。根据重大IAEs(ClassIntra ≥III)发生情况比较围术期结局。2018至2025年间共实施478例RAMIE。41例患者发生IAEs(8.6%;46起事件),其中92.7%在机器人下完成处理而未中转。出血是最常见事件(69.6%),其次为乳糜漏(8.7%)、肺损伤(8.7%)和气道损伤(4.3%)。20例患者发生重大IAEs(4.2%),与平均失血量增加(1211 vs. 296 mL,P<0.001)、中转率升高(15.0% vs. 1.3%,P=0.005)和平均手术时间延长(478.6 vs. 413.3 min,P=0.022)相关。重大术后并发症(35.0% vs. 37.3%,P=1.000)、中位住院时间(11 vs. 11 d,P=0.311)和院内死亡率(5.0% vs. 2.7%,P=0.446)在两组间相当。在该回顾性队列中,RAMIE期间超过90%的IAEs在机器人下处理而未中转,术后并发症发生率未见显著增加。这些结果应在专家中心且事件数量有限的背景下解读。

5直肠癌/TME (2篇)

临床研究 (2篇)

Pharmacological research IF 12.2 2026-11 PMID: 42901338
Neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced rectal cancer (LARC), yet its molecular determinants of response remain unclear. We conducted longitudinal 4D-DIA proteomic profiling of pre- and post-treatment specimens from 156 patients, including 31 patients with matched pre- and post-treatment specimens, and integrated with bulk RNA sequencing, single-cell transcriptomics, and functional validation. At baseline, responders were enriched in innate and adaptive immune pathways, whereas non-responders showed proliferative and metabolic programs. Pre-treatment RAC2, elevated in responders, was positively associated with immune activation, oxaliplatin sensitivity, and survival, and was validated in GSE139255 and GSE35640 (all P < 0.05). Moreover, RAC2 demonstrated strong predictive performance (training AUC = 0.867; testing AUC = 0.857). During treatment, NAC induced fibrosis-related remodeling across all groups (all P < 0.05), while responders uniquely preserved CD8⁺ T cell infiltration (P = 0.031). Responders and RAC2-high tumors exhibited concordant pathway dynamics during NAC. Single-cell analysis further revealed that pre-treatment tumor RAC2, higher in responders, transmitted signals to CD8⁺ T cells while receiving inputs from fibroblasts (P < 0.05). In vitro and in vivo, RAC2 knockdown reduced baseline tumor growth but promoted under oxaliplatin (all P < 0.05). Overall, this study offers proteomic insights into NAC in LARC, supports therapeutic decision-making, and identifies potential targets.
中文摘要:新辅助化疗(NAC)是局部晚期直肠癌(LARC)的标准治疗,但其应答的分子决定因素仍不清楚。我们对156例患者的治疗前和治疗后标本进行了纵向4D-DIA蛋白质组分析,其中31例具有配对的治疗前后标本,并与bulk RNA测序、单细胞转录组学和功能验证整合。基线时,应答者富集固有和适应性免疫通路,非应答者呈现增殖和代谢程序。治疗前RAC2在应答者中升高,与免疫激活、奥沙利铂敏感性和生存正相关,并在GSE139255和GSE35640中得到验证(均P<0.05)。RAC2显示出较强预测性能(训练AUC=0.867;测试AUC=0.857)。治疗期间,NAC在所有组中诱导纤维化相关重塑(均P<0.05),而应答者独特地保留了CD8⁺ T细胞浸润(P=0.031)。应答者和RAC2高表达肿瘤在NAC期间表现出一致的通路动态。单细胞分析进一步显示,治疗前肿瘤RAC2在应答者中较高,向CD8⁺ T细胞传递信号,同时接受成纤维细胞输入(P<0.05)。体外和体内,敲低RAC2降低基线肿瘤生长,但在奥沙利铂处理下促进生长(均P<0.05)。总体,本研究为LARC的NAC提供蛋白质组学见解,支持治疗决策,并识别潜在靶点。
Annals of surgery IF 7.4 2026-11-01 PMID: 42681563
To compare the safety and effectiveness of the Colovac Anastomosis Protection Device with standard diverting ostomy (DO) following low anterior resection (LAR) for rectal cancer. DO is standard of care (SOC) following LAR for rectal cancer but is associated with substantial morbidity. Colovac Device is designed to divert the fecal stream away from the anastomosis intraluminally. Three prospective multicenter Colovac trials were pooled and compared with a prospective cohort of patients undergoing LAR with DO for rectal cancer using a propensity score-weighted approach to balance baseline characteristics. The primary safety endpoint for both Colovac and SOC trials was the rate of device-related or stoma-related early major complications by POD10. Secondary endpoints included early anastomotic leak (AL) rates, fecal stream diversion effectiveness, and device migration. Patients were included (Colovac=49, DO=54). By POD10, device- or stoma-related major complications rates were 4.1% (2/49) vs 5.6% (3/54) ( P =0.167). All Colovac devices were successfully placed and retrieved with stoma avoidance achieved in 83.7% at POD10. Major complication rates were similar between groups. Rates of AL detected on POD9/10 were comparable between Colovac and control patients (28.6% vs. 20.4%, P =0.102), with total AL rate of 32.6% in Colovac versus 27.8% ( P =0.342) in control at POD30. Effective fecal diversion was achieved in 91.7% of Colovac patients, with device migration in 14.3%. Colovac enabled ostomy avoidance in most patients without increasing major complications or AL, suggesting its role as a potential alternative to DO following LAR for rectal cancer. SAFE-2019: NCT05180565; SAFE-2: NCT05010850; SAFE-2023: NCT06540807; SH-SOC23: NCT06152276.
中文摘要:比较直肠癌低位前切除(LAR)后Colovac吻合口保护装置与标准转流性造口(DO)的安全性和有效性。DO是直肠癌LAR后的标准治疗(SOC),但与较高的并发症负担相关。Colovac装置设计为在腔内将粪便流从吻合口引流开。汇总三项前瞻性多中心Colovac试验,并与接受LAR联合DO的直肠癌前瞻性队列比较,采用倾向评分加权平衡基线特征。两项试验的主要安全终点均为术后第10天(POD10)装置相关或造口相关早期主要并发症发生率。次要终点包括早期吻合口漏(AL)率、粪便转流有效性和装置移位。共纳入Colovac组49例、DO组54例。POD10装置相关或造口相关主要并发症发生率分别为4.1%(2/49)和5.6%(3/54)(P=0.167)。所有Colovac装置均成功置入和取出,POD10避免造口率达到83.7%。两组主要并发症发生率相似。POD9/10检测到的AL率在Colovac组和对照组间相当(28.6%对20.4%,P=0.102),POD30总AL率Colovac组为32.6%,对照组为27.8%(P=0.342)。Colovac组91.7%的患者实现有效粪便转流,装置移位发生率14.3%。Colovac使多数患者避免造口,且未增加主要并发症或AL,提示其可作为直肠癌LAR后DO的潜在替代方案。SAFE-2019:NCT05180565;SAFE-2:NCT05010850;SAFE-2023:NCT06540807;SH-SOC23:NCT06152276。

6结直肠外科 (2篇)

临床研究 (1篇)

Diabetologia IF 10.4 2026-11 PMID: 41973196
Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease in children and adolescents worldwide and is increasing alongside rising rates of paediatric obesity and type 2 diabetes. Paediatric MASLD most often arises in the setting of obesity and metabolic dysfunction but can occur without obesity and is influenced by early life exposures, genetics and environmental factors. Paediatric MASLD and youth-onset type 2 diabetes are tightly linked given the shared and bidirectional pathophysiological mechanisms. Hepatic steatosis often develops early in the course of insulin resistance, even in preschool-age children. Epidemiology in children varies by sex and ancestry and carries major prognostic implications, with a higher MASLD prevalence in male and Hispanic youth, more severe liver disease when MASLD coexists with impaired glucose tolerance or type 2 diabetes, and an alarming increased risk of mortality in late childhood and young adulthood. Paediatric MASLD is distinct from adult disease, with 20-25% of affected youth demonstrating clinically significant fibrosis on histology, distinct periportal (zone 1) patterns unique to childhood disease, and more severe liver histology in those with impaired glucose tolerance or diabetes. Early life determinants, such as maternal obesity and diabetes, are associated with childhood steatosis beginning early in life. Further, puberty represents a critical window of vulnerability, as physiological insulin resistance, sex-specific effects of androgens, and obesity-related metabolic stress drive sharp increases in both MASLD and youth-onset type 2 diabetes, with distinct sex differences in prevalence and severity. Current management for MASLD in paediatrics is evolving, relying primarily on lifestyle modification and targeted screening but with emerging evidence supporting the benefits of glucagon-like peptide-1 receptor agonists and bariatric surgery in selected youth with obesity, type 2 diabetes and related comorbidities, underscoring the urgent need for paediatric-specific therapeutic trials.
中文摘要:儿童代谢功能障碍相关脂肪性肝病(MASLD)是全球儿童和青少年慢性肝病的首要病因,并随儿童肥胖和2型糖尿病患病率上升而增加。儿童MASLD多发生于肥胖和代谢功能障碍背景,也可在无肥胖时出现,并受生命早期暴露、遗传和环境因素影响。儿童MASLD与青年起病2型糖尿病联系紧密,二者具有共享且双向的病理生理机制。肝脂肪变常在胰岛素抵抗早期出现,甚至可见于学龄前儿童。儿童中的流行病学因性别和血统而异并具有重要预后意义:男性和西班牙裔青年MASLD患病率更高;MASLD合并糖耐量受损或2型糖尿病时肝病更严重;儿童晚期和青年早期死亡风险升高令人担忧。儿童MASLD不同于成人疾病:20-25%受累青年组织学显示临床显著纤维化,存在儿童期特有的门管区周围(1区)模式,合并糖耐量受损或糖尿病者肝组织学更严重。生命早期决定因素如母亲肥胖和糖尿病与生命早期即开始的儿童脂肪变相关。青春期是脆弱的关键窗口,生理性胰岛素抵抗、雄激素的性别特异性作用及肥胖相关代谢应激推动MASLD和青年起病2型糖尿病均急剧增加,患病率和严重程度存在明显性别差异。儿童MASLD的当前管理仍在演变,主要依赖生活方式干预和针对性筛查,但新兴证据支持胰高血糖素样肽-1受体激动剂和减重手术对部分合并肥胖、2型糖尿病及相关合并症的青少年有益,凸显开展儿科特异性治疗试验的迫切需求。

基础研究 (1篇)

Genes & diseases IF 14.6 2026-11 PMID: 42491364
Therapeutic resistance continues to be a significant challenge in cancer treatment, often leading to tumor recurrence, metastasis, and limited therapeutic efficacy despite advancements in chemotherapy and radiotherapy. This resistance arises from complex molecular mechanisms that are influenced by various factors, including genetic alterations, epigenetic modifications, and cellular signaling. Recently, lncRNAs, a subclass of non-coding RNAs, have gained prominence for their essential role in driving cancer progression and mediating resistance to therapy. The resistance phenotype is shaped by lncRNAs through the regulation of key signaling pathways, DNA repair mechanisms, and cellular survival processes. For example, lncRNAs such as HOTAIR and MALAT1 are involved in the regulation of PI3K/AKT, EMT, and DNA repair pathways, and influence cell proliferation, apoptosis, and metastasis. These findings underscore the potential of lncRNAs as therapeutic targets. Targeting lncRNA-mediated pathways offers a promising approach to overcome resistance and enhance the efficacy of existing therapies. This review provides an in-depth analysis of the molecular mechanisms by which lncRNAs mediate resistance in various cancers, such as gastric cancer, lung cancer, breast cancer, and hepatocellular carcinoma. By focusing on the therapeutic potential of lncRNAs, we propose new avenues for overcoming resistance and improving treatment outcomes in cancer therapy.
中文摘要:治疗耐药仍是癌症治疗中的重大难题,尽管化疗和放疗已有进展,耐药仍常导致肿瘤复发、转移和治疗效果受限。耐药由复杂的分子机制产生,并受遗传改变、表观遗传修饰和细胞信号传导等多种因素影响。近年来,长链非编码RNA(lncRNA)作为非编码RNA的一个亚类受到关注,其在推动癌症进展和介导治疗耐药中具有重要作用。lncRNA通过调控关键信号通路、DNA修复机制和细胞存活过程塑造耐药表型。例如,HOTAIR和MALAT1等lncRNA参与调控PI3K/AKT、上皮-间质转化和DNA修复通路,并影响细胞增殖、凋亡和转移。这些发现凸显了lncRNA作为治疗靶点的潜力。靶向lncRNA介导的通路为克服耐药并提高现有疗法疗效提供了有前景的策略。该综述深入分析lncRNA在胃癌、肺癌、乳腺癌和肝细胞癌等多种癌症中介导耐药的分子机制。围绕lncRNA的治疗潜力,作者提出克服耐药并改善癌症治疗结局的新途径。

7胃癌外科 (2篇)

基础研究 (2篇)

Acta pharmacologica Sinica IF 10.4 2026-11 PMID: 41781700
Biomolecular condensates formed through liquid-liquid phase separation (LLPS) have emerged as central organizers of cellular biochemistry. In cancer, dysregulated phase separation gives rise to oncogenic condensates that reprogram transcriptional, signaling, and stress-response networks. By selectively concentrating oncogenic proteins and nucleic acids, these dynamic assemblies create permissive regulatory microenvironments that stabilize malignant cell states and facilitate therapeutic resistance. Accumulating evidence now indicates that oncogenic condensates are pharmacologically tractable, opening new opportunities for targeted intervention. In this Review, we synthesize current mechanistic insights into condensate assembly, regulation, and material state transitions; examine their context-dependent behaviors and functional heterogeneity across tumor ecosystems; and delineate emerging therapeutic strategies, including small-molecule modulators, peptide-based inhibitors, targeted protein degraders, and RNA-directed approaches. We further highlight recent translational advances-exemplified by DPTX-3186, a first-in-class condensate modulator granted FDA Orphan Drug Designation for Wnt-driven gastric cancer-that underscore the clinical promise of condensate-directed therapies. Finally, we discuss key mechanistic, pharmacodynamic, and biomarker-related challenges that must be addressed to fully integrate condensate biology into next-generation precision oncology.
中文摘要:通过液-液相分离(LLPS)形成的生物分子凝聚体已成为细胞生物化学的核心组织者。在癌症中,相分离失调产生致癌性凝聚体,重编程转录、信号传导和应激反应网络。这些动态组装体选择性富集致癌蛋白与核酸,形成有利于维持恶性细胞状态并促进治疗耐药的调控微环境。越来越多证据表明,致癌性凝聚体具有药理学可干预性,为靶向干预提供了新机会。本综述整合凝聚体组装、调控和物质状态转变的机制认识,考察其在肿瘤生态系统中的情境依赖行为与功能异质性,并梳理新兴治疗策略,包括小分子调节剂、肽类抑制剂、靶向蛋白降解剂和RNA导向方法。文中还强调近期转化进展,例如DPTX-3186这一首创凝聚体调节剂获FDA孤儿药资格用于Wnt驱动胃癌,显示凝聚体导向治疗的临床前景。最后讨论将凝聚体生物学纳入下一代精准肿瘤学所需解决的关键机制、药效学和生物标志物相关挑战。
Journal for immunotherapy of cancer IF 11.7 2026-10-30 PMID: 42963101
Tumor epigenetic reprogramming serves as a critical hallmark of cancer, fostering transcriptional plasticity of gene expression and driving alterations in the suppressive inflammatory responses within the tumor microenvironment, which pose significant challenges to the advancement of novel CAR-macrophage (CAR-M)-based antitumor therapies. However, it remains limited mechanistic investigations exploring how epigenetic reprogramming strategies impact the efficacy of CAR-M treatments. Human epidermal growth factor receptor 2 (HER2)-targeted CAR-Ms containing either an α1β1 integrin-mediated Fc-gamma receptor I (FcγRI) or CD3ζ signaling domain were generated and compared for tumor-directed migration and antitumor activity. HER2-positive tumor cells were pretreated with decitabine (DAC). CAR-M function, tumor-cell death, transcriptomic and inflammatory pathway changes, tumor immune remodeling, and therapeutic efficacy were assessed using in vitro assays, RNA sequencing, and murine tumor and metastasis models. Full-dose and half-dose CAR-M regimens were evaluated. α1β1 integrin-FcγRI CAR-Ms displayed significantly greater migration toward HER2-positive tumor cells than CD3ζ CAR-Ms. DAC potentiated anti-HER2 CAR-M activity by reprogramming tumor-cell gene expression and shifting the dominant cell-death mode from apoptosis to gasdermin E (GSDME)-dependent pyroptosis. RNA sequencing demonstrated enrichment of inflammatory immune-response programs, including nuclear factor kappa B and Janus kinase-signal transducer and activator of transcription signaling, after DAC treatment. DAC also favorably remodeled the tumor immune microenvironment, thereby supporting CAR-M activity. In murine models, DAC plus CAR-M therapy enhanced inflammatory antitumor immunity and improved control of primary tumor growth and metastatic disease compared with CAR-M monotherapy. Notably, DAC pretreatment combined with half-dose CAR-Ms achieved therapeutic efficacy comparable to that of full-dose CAR-M treatment. DAC-mediated DNA demethylation sensitizes HER2-positive tumors to CAR-M therapy through GSDME-dependent pyroptosis, activation of inflammatory signaling, and favorable remodeling of the tumor microenvironment. Epigenetic priming may improve CAR-M efficacy while reducing the required cell dose, supporting further translational development of this combination strategy for solid tumors.
中文摘要:肿瘤表观遗传重编程是癌症的重要标志,可促成基因表达的转录可塑性,并推动肿瘤微环境内抑制性炎症反应发生改变,这些因素对基于CAR巨噬细胞(CAR-M)的新型抗肿瘤疗法构成明显障碍。表观遗传重编程策略如何影响CAR-M疗效,相关机制研究仍有限。研究构建了含α1β1整合素介导的FcγRI信号域或CD3ζ信号域的靶向人表皮生长因子受体2(HER2)的CAR-M,并比较其向肿瘤定向迁移和抗肿瘤活性。HER2阳性肿瘤细胞先用去西他滨(DAC)预处理。通过体外实验、RNA测序及小鼠肿瘤与转移模型,评估CAR-M功能、肿瘤细胞死亡、转录组与炎症通路变化、肿瘤免疫重塑及治疗效果。并比较全剂量与半剂量CAR-M方案。α1β1整合素-FcγRI CAR-M向HER2阳性肿瘤细胞的迁移显著强于CD3ζ CAR-M。DAC通过重编程肿瘤细胞基因表达、使主导性细胞死亡方式由凋亡转向gasdermin E(GSDME)依赖的细胞焦亡,从而增强抗HER2 CAR-M活性。RNA测序显示,DAC处理后炎症免疫反应程序富集,包括核因子κB与Janus激酶-信号转导及转录激活因子信号通路。DAC还良性重塑肿瘤免疫微环境,进而支持CAR-M活性。在小鼠模型中,与CAR-M单药相比,DAC联合CAR-M治疗增强了炎症性抗肿瘤免疫,并改善对原发肿瘤生长和转移病灶的控制。DAC预处理联合半剂量CAR-M所达到的疗效与全剂量CAR-M治疗相当。DAC介导的DNA去甲基化通过GSDME依赖的细胞焦亡、炎症信号激活及肿瘤微环境的良性重塑,使HER2阳性肿瘤对CAR-M治疗增敏。表观遗传预处理可在降低所需细胞剂量的同时提高CAR-M疗效,支持这一联合策略用于实体瘤的进一步转化开发。